In particular, GFPT1 reduced activity was associated with a destabilization of the PD-L1 protein in lung cancer, limiting the effects of immunotherapies.39 This is line with the extremely low expression level of PD-L1 at the surface of pLGG tumor cells,40 and the fact that MAPK activity can promote an immunosuppressive microenvironment via a downregulation of PD-1/PD-L1 molecules, as observed in colorectal cancer or melanoma.41,42 This suggest that such a combination of MAPKi and ICI could be promising in pLGG and warrants further evaluation. The gene discussed is GFPT1; the disease is lung carcinoma.